Spots Global Cancer Trial Database for pazopanib hydrochloride
Every month we try and update this database with for pazopanib hydrochloride cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pazopanib in Treating Patients With Recurrent Glioblastoma | NCT00459381 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Recurrent Adult... | pazopanib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy | NCT01208064 | Lung Cancer | pazopanib hydro... laboratory biom... pharmacogenomic... pharmacological... quality-of-life... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | NCT01465659 | Pancreatic Alph... Pancreatic Beta... Pancreatic Delt... Pancreatic G-ce... Recurrent Islet... | temozolomide pazopanib hydro... | 18 Years - | Northwestern University | |
| Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | NCT01684397 | Clear Cell Rena... Stage IV Renal ... | Bevacizumab Laboratory Biom... Pazopanib Hydro... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | NCT00454571 | Recurrent Prost... | pazopanib hydro... leuprolide acet... goserelin aceta... | 18 Years - | National Cancer Institute (NCI) | |
| Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | NCT01664182 | Advanced Renal ... Advanced Sarcom... Stage III Renal... Stage IV Renal ... | Bevacizumab Pazopanib Hydro... Sorafenib Tosyl... Sunitinib Malat... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | NCT00929903 | Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Metastatic Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Unspecified Chi... | pazopanib hydro... pharmacological... | 2 Years - 25 Years | National Cancer Institute (NCI) | |
| Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer | NCT01599832 | Clear Cell Rena... Recurrent Renal... Stage IV Renal ... | pazopanib hydro... laboratory biom... dynamic contras... pharmacogenomic... | 18 Years - | University of Chicago | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas | NCT03660930 | Advanced Soft T... Locally Advance... Metastatic Soft... | Sirolimus Album... Pazopanib hydro... | 18 Years - | University of Washington | |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | NCT01462630 | Adult Angiosarc... Recurrent Adult... Stage III Adult... Stage IV Adult ... | pazopanib hydro... laboratory biom... positron emissi... computed tomogr... fludeoxyglucose... | 18 Years - | Fox Chase Cancer Center | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | NCT01841736 | Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest... | Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery | NCT00450879 | Male Breast Car... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... | Pazopanib Hydro... Dynamic Contras... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | NCT02307474 | Clear Cell Rena... Renal Cell Carc... | Stereotactic Ra... Pazopanib Hydro... | 18 Years - | Case Comprehensive Cancer Center | |
| Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery | NCT01413113 | Recurrent Thyro... Stage IVA Folli... Stage IVA Papil... Stage IVB Folli... Stage IVB Papil... Stage IVC Folli... Stage IVC Papil... | pazopanib hydro... iodine I 131 | 18 Years - | University of Washington | |
| Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | NCT01446809 | Stage IIA Adult... Stage III Adult... Stage IV Adult ... | Doxorubicin Hyd... External Beam R... Ifosfamide Laboratory Biom... Pazopanib Hydro... Pharmacological... Placebo Therapeutic Con... | 18 Years - | University of Washington | |
| Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer | NCT00509587 | Breast Cancer Recurrent Breas... Stage IV Breast... | pazopanib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | NCT02180867 | Alveolar Soft P... Angiomatoid Fib... Atypical Fibrox... Clear Cell Sarc... Epithelioid Mal... Epithelioid Sar... Extraskeletal M... Extraskeletal O... Fibrohistiocyti... Fibrosarcoma Inflammatory My... Intimal Sarcoma Leiomyosarcoma Liposarcoma Liver Embryonal... Low Grade Fibro... Low Grade Myofi... Malignant Cutan... Malignant Perip... Malignant Trito... Mesenchymal Cho... Myxofibrosarcom... Myxoid Chondros... Myxoinflammator... Nerve Sheath Ne... PEComa Pericytic Neopl... Plexiform Fibro... Sclerosing Epit... Skin Glomus Tum... Stage IB Soft T... Stage IIB Soft ... Stage III Soft ... Stage IV Soft T... Synovial Sarcom... Undifferentiate... | Doxorubicin Doxorubicin Hyd... Ifosfamide Pazopanib Pazopanib Hydro... Radiation Thera... Therapeutic Con... | 2 Years - | National Cancer Institute (NCI) | |
| S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors | NCT00788580 | Unspecified Adu... | pazopanib hydro... temsirolimus immunoenzyme te... laboratory biom... pharmacological... | 18 Years - | SWOG Cancer Research Network | |
| Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | NCT02601209 | High Grade Sarc... Metastatic Leio... Metastatic Mali... Metastatic Syno... Metastatic Undi... Metastatic Unre... Myxofibrosarcom... Recurrent Leiom... Recurrent Malig... Recurrent Synov... Recurrent Undif... Stage III Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... Unresectable Le... | Pazopanib Pazopanib Hydro... Sapanisertib | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer | NCT00509587 | Breast Cancer Recurrent Breas... Stage IV Breast... | pazopanib hydro... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery | NCT00450879 | Male Breast Car... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage IIA Breas... Stage IIB Breas... Stage IIIA Brea... | Pazopanib Hydro... Dynamic Contras... Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer | NCT01394211 | Estrogen Recept... Human Epidermal... Male Breast Can... Recurrent Breas... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... | anastrozole pazopanib hydro... therapeutic con... | 18 Years - | University of Arizona | |
| Pazopanib in Treating Patients With Malignant Pleural Mesothelioma | NCT00459862 | Advanced Malign... Localized Malig... Recurrent Malig... | laboratory biom... pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| GW786034 in Treating Patients With Advanced Solid Tumors | NCT00060151 | Unspecified Adu... | pazopanib hydro... | 21 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma | NCT01462630 | Adult Angiosarc... Recurrent Adult... Stage III Adult... Stage IV Adult ... | pazopanib hydro... laboratory biom... positron emissi... computed tomogr... fludeoxyglucose... | 18 Years - | Fox Chase Cancer Center | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery | NCT00861913 | Recurrent Melan... Stage IV Cutane... | Laboratory Biom... Pazopanib Hydro... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer | NCT00454142 | Recurrent Lymph... Recurrent Squam... Stage IV Lympho... Stage IV Squamo... | pazopanib hydro... pharmacological... computed tomogr... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy | NCT01208064 | Lung Cancer | pazopanib hydro... laboratory biom... pharmacogenomic... pharmacological... quality-of-life... | 18 Years - 120 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment | NCT01031875 | Bladder Cancer Transitional Ce... Urethral Cancer | pazopanib hydro... fludeoxyglucose... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma | NCT01340794 | Extra-Adrenal P... Metastatic Adre... Paraganglioma Recurrent Adren... | Laboratory Biom... Pazopanib Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | NCT01713972 | Unspecified Adu... | dabrafenib pazopanib hydro... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery | NCT03334409 | Clear Cell Rena... Metastatic Clea... Stage III Renal... Stage IV Renal ... Unresectable Re... | Ascorbic Acid Pazopanib Hydro... | 18 Years - | Academic and Community Cancer Research United | |
| Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | NCT00625846 | Recurrent Thyro... Stage III Diffe... Stage III Thyro... Stage IVA Diffe... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Diffe... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Diffe... Stage IVC Thyro... Stage IVC Thyro... Thyroid Gland A... | Laboratory Biom... Pazopanib Hydro... | 19 Years - | National Cancer Institute (NCI) | |
| Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | NCT01468909 | Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Laboratory Biom... Paclitaxel Pazopanib Hydro... Placebo | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00486642 | Hormone-Resista... Recurrent Prost... | Bicalutamide Laboratory Biom... Pazopanib Hydro... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | NCT01767636 | Carcinoma of th... Chromophobe Ren... Kidney Medullar... Kidney Oncocyto... Metastatic Rena... Papillary Renal... Recurrent Renal... Sarcomatoid Ren... Stage IV Renal ... | Pazopanib Hydro... | 18 Years - | Mayo Clinic | |
| Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | NCT00929903 | Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Childhood Centr... Metastatic Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Unspecified Chi... | pazopanib hydro... pharmacological... | 2 Years - 25 Years | National Cancer Institute (NCI) | |
| Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | NCT01713972 | Unspecified Adu... | dabrafenib pazopanib hydro... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | NCT01236547 | Thyroid Gland A... | Intensity-Modul... Paclitaxel Pazopanib Hydro... Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery | NCT01413113 | Recurrent Thyro... Stage IVA Folli... Stage IVA Papil... Stage IVB Folli... Stage IVB Papil... Stage IVC Folli... Stage IVC Papil... | pazopanib hydro... iodine I 131 | 18 Years - | University of Washington | |
| Pazopanib in Treating Patients With Metastatic Urothelial Cancer | NCT00471536 | Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | NCT01841736 | Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest... | Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | NCT01247571 | Recurrent Uteri... Uterine Carcino... | Pazopanib Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors | NCT01552356 | Solid Neoplasm | Laboratory Biom... Pazopanib Hydro... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | NCT01402271 | Fallopian Tube ... Ovarian Cancer Primary Periton... | carboplatin paclitaxel pazopanib hydro... laboratory biom... pharmacological... | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | NCT01158521 | Clear Cell Rena... Stage I Renal C... Stage II Renal ... Stage III Renal... | pazopanib hydro... therapeutic con... | 18 Years - | Case Comprehensive Cancer Center | |
| Pazopanib in Treating Patients With Malignant Pleural Mesothelioma | NCT00459862 | Advanced Malign... Localized Malig... Recurrent Malig... | laboratory biom... pazopanib hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer | NCT00454571 | Recurrent Prost... | pazopanib hydro... leuprolide acet... goserelin aceta... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
